» Articles » PMID: 1909090

Gaucher Disease: Heterologous Expression of Two Alleles Associated with Neuronopathic Phenotypes

Overview
Journal Am J Hum Genet
Publisher Cell Press
Specialty Genetics
Date 1991 Sep 1
PMID 1909090
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

To investigate the molecular basis for the distinct neuronopathic phenotypes of Gaucher disease, acid beta-glucosidases expressed from mutant DNAs in Gaucher disease type 2 (acute) and type 3 (subacute) patients were characterized in fibroblasts and with the baculovirus expression system in insect cells. Expression of the mutant DNA encoding a proline-for-leucine substitution at amino acid 444 (L444P) resulted in a catalytically defective, unstable acid beta-glucosidase in either fibroblasts from L444P/L444P homozygotes or in insect cells. This mutation was found to be homoallelic in subacute neuronopathic (type 3) Gaucher disease. In comparison, expression of the mutant cDNA encoding an arginine-for-proline substitution at amino acid 415 (P415R) resulted in an inactive and unstable protein in insect cells. This allele was found only in a type 2 patient with the L444P/P415R genotype. The substantial variation in the type 3 phenotype (L444P homozygotes) suggests the complex nature of the molecular basis of phenotypic variation in Gaucher disease. Yet, the association of neuronopathic phenotypes with alleles producing severely compromised (L444P) or functionally null (P415R) enzymes indicates that the effective level of residual activity at the lysosome is likely to be a major determinant of the severity of Gaucher disease.

Citing Articles

Inhibition of cysteine protease cathepsin L increases the level and activity of lysosomal glucocerebrosidase.

Kim M, Kim S, Reinheckel T, Krainc D JCI Insight. 2024; 9(3).

PMID: 38329128 PMC: 10967467. DOI: 10.1172/jci.insight.169594.


In Silico Analysis of Missense Mutations as a First Step in Functional Studies: Examples from Two Sphingolipidoses.

Duarte A, Ribeiro D, Moreira L, Amaral O Int J Mol Sci. 2018; 19(11).

PMID: 30384423 PMC: 6275066. DOI: 10.3390/ijms19113409.


Participation of asparagine 370 and glutamine 235 in the catalysis by acid beta-glucosidase: the enzyme deficient in Gaucher disease.

Liou B, Grabowski G Mol Genet Metab. 2009; 97(1):65-74.

PMID: 19217815 PMC: 2699545. DOI: 10.1016/j.ymgme.2009.01.006.


Non-pseudogene-derived complex acid beta-glucosidase mutations causing mild type 1 and severe type 2 gaucher disease.

Grace M, Ashton-Prolla P, Pastores G, Soni A, Desnick R J Clin Invest. 1999; 103(6):817-23.

PMID: 10079102 PMC: 408142. DOI: 10.1172/JCI5168.


Identification and expression of acid beta-glucosidase mutations causing severe type 1 and neurologic type 2 Gaucher disease in non-Jewish patients.

Grace M, Desnick R, Pastores G J Clin Invest. 1997; 99(10):2530-7.

PMID: 9153297 PMC: 508094. DOI: 10.1172/JCI119437.


References
1.
Taylor J, Schmidt W, Cosstick R, Okruszek A, Eckstein F . The use of phosphorothioate-modified DNA in restriction enzyme reactions to prepare nicked DNA. Nucleic Acids Res. 1985; 13(24):8749-64. PMC: 318949. DOI: 10.1093/nar/13.24.8749. View

2.
Mueller O, Rosenberg A . beta-Glucoside hydrolase activity of normal and glucosylceramidotic cultured human skin fibroblasts. J Biol Chem. 1977; 252(3):825-9. View

3.
Chen E, Seeburg P . Supercoil sequencing: a fast and simple method for sequencing plasmid DNA. DNA. 1985; 4(2):165-70. DOI: 10.1089/dna.1985.4.165. View

4.
Kolodny E, Firon N, Eyal N, Horowitz M . Mutation analysis of an Ashkenazi Jewish family with Gaucher disease in three successive generations. Am J Med Genet. 1990; 36(4):467-72. DOI: 10.1002/ajmg.1320360419. View

5.
Dahl N, Lagerstrom M, Erikson A, Pettersson U . Gaucher disease type III (Norrbottnian type) is caused by a single mutation in exon 10 of the glucocerebrosidase gene. Am J Hum Genet. 1990; 47(2):275-8. PMC: 1683716. View